EUVIMEDEUVIMED entdecken
Multizentrische Studie

5-Year Prospective Evaluation of Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Outcomes

Mayra E Guerrero, Mackram F Eleid, Dee Dee Wang, Amit Pursnani, Susheel K Kodali, Isaac George, Igor Palacios, Hyde Russell, Raj R Makkar, Saibal Kar, Lowell F Satler, Vivek Rajagopal und 16 weitere

JACC: Cardiovascular Interventions · 2023-09 · 16 (18) · 2211-2227

DOI: 10.1016/j.jcin.2023.06.041 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2023-09. Verfasst von Mayra E Guerrero und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: guerrero.mayra@mayo.edu. Hauptthemen laut MEDLINE: Heart Valve Prosthesis Implantation, Heart Valve Diseases, Heart Valve Prosthesis, Mitral Valve Insufficiency. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The MITRAL (Mitral Implantation of Transcatheter Valves) trial is the first prospective trial to evaluate the safety and feasibility of balloon-expandable aortic transcatheter heart valves in patients with failed surgical bioprostheses or annuloplasty rings and severe mitral annular calcification treated with mitral valve-in-valve (MViV), valve-in-ring (MViR), or valve-in-mitral annular calcification (ViMAC). OBJECTIVES: The aim of this study was to evaluate 5-year outcomes among these patients. METHODS: A multicenter prospective study was conducted among patients at high surgical risk at 13 U.S. sites. Patients underwent MViV (n = 30), MViR (n = 30), or ViMAC (n = 31) and were followed annually for 5 years. Kansas City Cardiomyopathy Questionnaire scores were obtained at baseline and follow-up visits. Echocardiograms were analyzed at independent core laboratories. RESULTS: A total of 91 patients underwent transcatheter mitral valve replacement (February 2015 to December 2017). The mean age was 74.3 ± 8.9 years. At 5-year follow-up, the lowest all-cause mortality was observed in the MViV group (21.4%), 94.7% of patients were in NYHA functional class I or II, and the mean mitral gradient was 6.6 ± 2.5 mm Hg. The MViR and ViMAC groups had higher all-cause mortality (65.5% and 67.9%), most survivors were in NYHA functional classes I and II (50% and 55.6%), and mean mitral gradients remained stable (5.8 ± 0.1 and 6.7 ± 2.5 mm Hg). Significant improvements in Kansas City Cardiomyopathy Questionnaire scores were observed when all 3 arms were pooled. CONCLUSIONS: MViV, MViR, and ViMAC procedures were associated with sustained improvement of heart failure symptoms and quality of life among survivors at 5 years. Transcatheter heart valve function remained stable in all 3 groups. Patients treated with MViV had excellent survival at 5 years, whereas survival was lower in the MViR and ViMAC groups, consistent with underlying disease severity. Patients with more residual mitral regurgitation had higher mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Valve Prosthesis ImplantationHeart Valve DiseasesHeart Valve ProsthesisMitral Valve InsufficiencyCalcinosisVascular DiseasesCardiomyopathiesHumansAgedAged, 80 and overMitral ValveProspective StudiesQuality of LifeTreatment OutcomeCardiac Catheterization

Stichwörter der Autor:innen

mitral annular calcificationmitral regurgitationmitral stenosismitral valve-in-valvetranscatheter mitral valve replacement

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: guerrero.mayra@mayo.edu.
  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Center for Structural Heart Disease, Henry Ford Hospital, Detroit, Michigan, USA.
  • Division of Cardiology, NorthShore University HealthSystem, Evanston, Illinois, USA.
  • Division of Cardiology, Columbia University Medical Center, New York, New York, USA.
  • Department of Surgery, Columbia University Medical Center, New York, New York, USA.

Zitieren

APA

Guerrero, M. E., Eleid, M. F., Wang, D. D., Pursnani, A., Kodali, S. K., George, I., Palacios, I., Russell, H., Makkar, R. R., Kar, S., Satler, L. F., Rajagopal, V., Dangas, G., Tang, G. H. L., McCabe, J. M., Whisenant, B. K., Fang, K., Balan, P., Smalling, R., …, & Rihal, C. (2023). 5-Year Prospective Evaluation of Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Outcomes. JACC: Cardiovascular Interventions, 16(18), 2211-2227. https://doi.org/10.1016/j.jcin.2023.06.041

Vancouver

Guerrero ME, Eleid MF, Wang DD, Pursnani A, Kodali SK, George I, et al. 5-Year Prospective Evaluation of Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Outcomes. JACC: Cardiovascular Interventions. 2023;16(18):2211-2227. doi:10.1016/j.jcin.2023.06.041

BibTeX
@article{Guerrero2023,
  author = {Guerrero, Mayra E and Eleid, Mackram F and Wang, Dee Dee and Pursnani, Amit and Kodali, Susheel K and George, Isaac and Palacios, Igor and Russell, Hyde and Makkar, Raj R and Kar, Saibal and Satler, Lowell F and Rajagopal, Vivek and Dangas, George and Tang, Gilbert H L and McCabe, James M and Whisenant, Brian K and Fang, Kenith and Balan, Prakash and Smalling, Richard and Kaptzan, Tatiana and Lewis, Bradley and Douglas, Pamela S and Hahn, Rebecca T and Thaden, Jeremy and Oh, Jae K and Leon, Martin and O'Neill, William and Rihal, Charanjit},
  title = {5-Year Prospective Evaluation of Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Outcomes},
  journal = {JACC: Cardiovascular Interventions},
  year = {2023},
  volume = {16},
  number = {18},
  pages = {2211--2227},
  doi = {10.1016/j.jcin.2023.06.041}
}
Kostenlos starten →